Research analysts at StockNews.com have recently initiated coverage on Alnylam Pharmaceuticals (NASDAQ:ALNY), issuing a “buy” rating on the biopharmaceutical company’s stock. Alnylam Pharmaceuticals is a commercial-stage biopharmaceutical company that specializes in the discovery, development, and commercialization of RNAi therapeutics. The company’s products include ONPATTRO, GIVLAARI, and OXLUMO.
In its most recent quarterly earnings report released on May 4th, Alnylam Pharmaceuticals reported an EPS of ($1.40) for the quarter, which exceeded analysts’ consensus estimates of ($1.97) by $0.57. Additionally, the business generated revenue of $319.29 million during the quarter, compared to the estimated $312.53 million consensus estimate.
Despite reporting negative return on equity and net margin percentages for Q1 2021, Alnylam Pharmaceuticals saw its quarterly revenue increase by almost 50% year-over-year when compared to Q1 2020 (when earning per share was ($2.00)). Analysts predict that Alnylam Pharmaceuticals will have an EPS of -6.59 for the fiscal year.
Alnylam Pharmaceuticals was founded by Nobel Laureate David Bartel along with Thomas Tuschl, Phillip Zamore, and Paul R., focusing on RNAi therapeutics to target specific genes responsible for certain diseases or disorders. ALNY is part of NASDAQ Biotechnology Index and has been associated with novel therapies developed based on messenger RNA technologies used in cancer therapies.
Overall, analysts at StockNews.com remain optimistic about Alnylam Pharmaceuticals’ potential in developing innovative RNAi-based treatments moving forward while acknowledging risks inherent in drug development programs but expect growing markets for these medicines over time could deliver significant value creation potential for shareholders as well as pose opportunities across collaborative partnerships within health-care industry albeit not without considerable investment over long term. Nonetheless, Alnylam Pharmaceuticals’ research and development capabilities together with promising results in clinical trials has earned the company a favorable outlook among some investors and analysts.
[bs_forecast_slider ticker=”ALNY”]
Alnylam Pharmaceuticals Rated Favorably by Research Analysts Despite Global Economic Pressures
Alnylam Pharmaceuticals Inc (NASDAQ:ALNY) has received several buy and outperform rating reports from different research analysts, despite facing the pressures of the global economic crisis. HC Wainwright, Sanford C. Bernstein, Canaccord Genuity Group, BMO Capital Markets, and EF Hutton Acquisition Co. I have all issued favorable ratings for ALNY stock. The average rating for Alnylam Pharmaceuticals on Bloomberg.com is “Moderate Buy,” with target price estimates at $247.20.
NASDAQ:ALNY opened trading at $193.23 on Thursday, with a market cap of $24.06 billion and a PE ratio of -22.24. The company’s shares are within the 52-week range between $120.43 and $242.97.
Alnylam Pharmaceuticals Inc specializes in RNAi therapeutics development, with ONPATTRO, GIVLAARI, and OXLUMO among its top products in the market today. The company was founded by Nobel Laureate David Bartel, Thomas Tuschl, Phillip Zamore, and Paul R.
Recent insider selling transactions involved CEO Yvonne Greenstreet selling 7,615 shares worth approximately $1,481,802 on April 27th while CFO Jeffrey V Poulton sold 977 shares worth $190,114 on the same day.
Several investment firms have modified their holdings in the company recently including Belpointe Asset Management LLC buying a new stake in Alnylam Pharmaceuticals last quarter valued at $25K while Guardian Wealth Advisors LLC bought one worth $27K during Q3 of last year; ANTIPODES PARTNERS Ltd took a position during Q4 by acquiring one valued around $28K while KB Financial Partners LLC entered last quarter with a purchase valued at around $35k; Archer Investment Corp also invested in the first quarter of this year with a purchase value of about$40k.
Despite recent insider activity and fluctuations in the market, Alnylam Pharmaceuticals remains an attractive investment option based on its rating from several research analysts. The company is expected to experience growth in the coming months as it continues to expand its offering of RNAi therapeutics into new markets. Prospective investors could consider taking a position in ALNY stock today.